4-羟基-2-丙基戊酸 | 60113-82-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 4-羟基-2-丙基戊酸
• 英文名称: 4-Hydroxyvalproic acid
• 英文别名: 2-n-propyl-4-hydroxypentanoic acid；4-hydroxy-valproic acid；4-hydroxy-2-propyl-valeric acid；γ-Oxy-α-propyl-n-valeriansaeure；β-Oxy-heptan-δ-carbonsaeure；4-hydroxy-2-propylpentanoic acid
• CAS: 60113-82-8
• 化学式: C₈H₁₆O₃
• 分子量: 160.213
• InChiKey: OASKNPCLIHUTTL-UHFFFAOYSA-N

物化性质

• 沸点：
  297.5±23.0 °C(Predicted)
• 密度：
  1.043±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

ADMET

代谢

4-羟基戊丙酸是戊酸的一种已知人体代谢物。

4-Hydroxyvalproate is a known human metabolite of valproic acid.

来源:NORMAN Suspect List Exchange

安全信息

• 海关编码：
  2918199090

反应信息

• 作为反应物：
  描述：

  4-羟基-2-丙基戊酸 在 盐酸 、 磷酸 作用下， 反应 3.0h， 生成 (3R,5S)-5-Methyl-3-propyl-dihydro-furan-2-one 、 (3R,5R)-5-Methyl-3-propyl-dihydro-furan-2-one
  参考文献：
  名称：

  Oxygenation Reaction of Methyl Valproate with A Mono-oxygenase Model Reagent: Implication for Stereochemical Identification of the Mammalian Metabolites of Valproic Acid.

  摘要：

  关于1的哺乳动物代谢物的立体化学分析，研究了利用单加氧酶的简单模型系统Fe(MeCN)2+6-H2O2-Ac2O在MeCN中对甲基戊二酸酯（2）的非酶氧合反应。甲基戊二酸酯（2）的这种氧合反应得到了反式异构体4a和顺式异构体4b的92:8混合物，以及对应于1的哺乳动物代谢物的5a和5b。通过光谱分析由氧合产物制备的相应β-内酯6a、γ-内酯7a和7b，阐明了4a、5a和5b的立体化学。也实现了（+）-7a的不对称合成。

  DOI：

  10.1248/cpb.45.981
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 作用下， 生成 4-羟基-2-丙基戊酸
  参考文献：
  名称：

  Hjelt, Chemische Berichte, 1896, vol. 29, p. 1857

  摘要：

  DOI：

文献信息

• Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use
  申请人：Christian T. Samuel

  公开号：US20060189547A1

  公开（公告）日：2006-08-24

  Hydrophilic N-linked pharmaceutical compositions, methods of their preparation and use in neuraxial drug delivery comprising a glycosyl CNS acting prodrug compound covalently N-linked with a saccharide through an amide or an amine bond and a formulary consisting of an additive, a stabilizer, a carrier, a binder, a buffer, an excipient, an emollient, a disintegrant, a lubricating agent, an antimicrobial agent or a preservative, with the proviso that the saccharide moiety is not a cyclodextrin or a glucuronide.

  亲水性N-连接药物组合物，其制备方法和在神经轴向药物输送中的使用，包括一种糖基中枢神经系统作用前药化合物，通过酰胺或胺键与糖苷共价连接，并且配方包括添加剂、稳定剂、载体、粘合剂、缓冲剂、赋形剂、润肤剂、破碎剂、润滑剂、抗微生物剂或防腐剂，但前提是糖苷基团不是环糊精或葡萄糖醛酸盐。
• Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use
  申请人：Christian Samuel T.

  公开号：US20110237544A1

  公开（公告）日：2011-09-29

  Hydrophilic N-linked pharmaceutical compositions, methods of their preparation and use in neuraxial drug delivery comprising a glycosyl CNS acting prodrug compound covalently N-linked with a saccharide through an amide or an amine bond and a formulary consisting of an additive, a stabilizer, a carrier, a binder, a buffer, an excipient, an emollient, a disintegrant, a lubricating agent, an antimicrobial agent or a preservative, with the proviso that the saccharide moiety is not a cyclodextrin or a glucuronide.

  亲水性N-连接的药物组成物、其制备方法和在神经轴药物输送中的使用，包括一种糖基CNS作用的前药化合物，通过酰胺或胺键与糖分子共价连接，并由添加剂、稳定剂、载体、粘合剂、缓冲剂、赋形剂、润肤剂、崩解剂、润滑剂、抗微生物剂或防腐剂组成的制剂，前提是糖分子部分不是环糊精或葡糖醛酸盐。
• Brain-specific drug delivery
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0218300A2

  公开（公告）日：1987-04-15

  The invention provides compounds adapted for the site-specific/sustained delivery of a centrally acting drug species to the brain having the formula [D-DHC] and the non- toxic pharmaceutically acceptable salts thereof, wherein [D] is a centrally acting drug species containing at least one reactive -OH, -COOH, -SH, -NH- or -NH2 functional group and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine ⇒ pyridinium salt redox carrier comprising a dihydroquinoline or dihydroisoquinoline ring system, a carbon atom of the nitrogen-containing ring portion of said ring system being connected via a bridging group to a reactive -OH, -COOH, -SH, -NH- or -NH2 functional group in the centrally acting drug species. The corresponding quaternary derivatives are also described.

  本发明提供了适用于向脑部定点/持续递送具有式[D-DHC]的中枢作用药物种类的化合物及其无毒药学上可接受的盐，其中[D]是含有至少一个活性-OH、-COOH、-SH、-NH-或-NH2官能团的中枢作用药物种类，[DHC]是还原的、可生物氧化的、二氢吡啶⇒吡啶鎓盐氧化还原载体的脂质形式，该载体包含二氢喹啉或二氢异喹啉环系统，所述环系统含氮环部分的碳原子通过桥基与中枢作用药物种类中的活性-OH、-COOH、-SH、-NH-或-NH2 官能团相连。还描述了相应的季衍生物。
• Pharmaceutical formulations for parenteral use
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0335545A2

  公开（公告）日：1989-10-04

  Aqueous parenteral solutions of drugs which are insoluble or only sparingly'soluble in water and/or which are unstable in water, combined with a hydroxypropyl,hydroxyethyl, glucosyl, maltosyl or maltotriosyl derivative of 3-or γ-cyclodextrin, provide a means for alleviating problems associated with drug precipitation at the injection site and/or in the lungs or other organs following parenteral administration.

  不溶于水或只能少量溶于水和/或在水中不稳定的药物的肠外水溶液与 3-或 γ-环糊精的羟丙基、羟乙基、葡糖基、麦芽糖基或麦芽三糖基衍生物结合使用，可以缓解肠外给药后药物在注射部位和/或肺部或其他器官沉淀的问题。
• Redox systems for brain-targeted drug delivery
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0327766A2

  公开（公告）日：1989-08-16

  Inclusion complexes of hydroxypropyl, hydroxyethyl, glucosyl, maltosyl or maltotriosyl derivatives of β- or γ-cyclodextrin with the reduced, biooxidizable, blood-brain barrier penetrating, lipoidal forms of dihydropyridine = pyridinium salt redox systems for brain-targeted drug delivery provide a means for stabilizing the redox systems, particularly against oxidation. The redox inclusion complexes also provide a means for decreasing initial drug concentrations in the lungs after administration of the systems, leading to decreased toxicity. In selected instances, complexation results in substantially improved water solubility of the redox systems as well.

  β-或γ-环糊精的羟丙基、羟乙基、葡糖基、麦芽糖基或麦芽三糖基衍生物与还原型、可生物氧化、可穿透血脑屏障、类脂形式的二氢吡啶＝吡啶鎓盐氧化还原体系的包合物为脑靶向给药提供了一种稳定氧化还原体系，特别是防止氧化的方法。氧化还原包合物还能降低给药后肺部的初始药物浓度，从而降低毒性。在某些情况下，络合物还能大大提高氧化还原体系的水溶性。